Little is known about the acute effects of antidepressant treatments on brain glutamate and gamma-aminobutyric acid (GABA) levels, and their association with clinical response. Using proton magnetic resonance spectroscopy ( 1 H-MRS) we examined longitudinally the effects of citalopram on glutamine/glutamate ratios and GABA levels in the pregenual anterior cingulate cortex (pgACC) of individuals with major depressive disorder (MDD). We acquired 1 H-MRS scans at baseline and at days 3, 7, and 42 of citalopram treatment in nineteen unmedicated individuals with MDD. Ten age-and sex-matched non-depressed comparison individuals were scanned once. The association between 1) baseline metabolites and 2) change in metabolites from baseline to each time point and clinical response (change in Montgomery-Åsberg Depression Rating Scale (MADRS) score from baseline to day 42) was assessed by longitudinal regression analysis using generalized estimating equations. Contrary to our hypotheses, no significant associations emerged between glutamate metabolites and clinical response; however, greater increases (or smaller decreases) in pgACC GABA levels from baseline to days 3 and 7 of citalopram treatment were significantly associated with clinical response. These findings suggest that an acute change in GABA levels in pgACC predicts, and possibly mediates, later clinical response to citalopram treatment in individuals with MDD.
A R T I C L E I N F O
Keywords: Depression SSRI Glutamate GABA Magnetic resonance spectroscopy MRS
A B S T R A C T
Little is known about the acute effects of antidepressant treatments on brain glutamate and gamma-aminobutyric acid (GABA) levels, and their association with clinical response. Using proton magnetic resonance spectroscopy ( 1 H-MRS) we examined longitudinally the effects of citalopram on glutamine/glutamate ratios and GABA levels in the pregenual anterior cingulate cortex (pgACC) of individuals with major depressive disorder (MDD). We acquired 1 H-MRS scans at baseline and at days 3, 7, and 42 of citalopram treatment in nineteen unmedicated individuals with MDD. Ten age-and sex-matched non-depressed comparison individuals were scanned once. The association between 1) baseline metabolites and 2) change in metabolites from baseline to each time point and clinical response (change in Montgomery-Åsberg Depression Rating Scale (MADRS) score from baseline to day 42) was assessed by longitudinal regression analysis using generalized estimating equations. Contrary to our hypotheses, no significant associations emerged between glutamate metabolites and clinical response; however, greater increases (or smaller decreases) in pgACC GABA levels from baseline to days 3 and 7 of citalopram treatment were significantly associated with clinical response. These findings suggest that an acute change in GABA levels in pgACC predicts, and possibly mediates, later clinical response to citalopram treatment in individuals with MDD.
Introduction
Major depressive disorder (MDD) is common, disabling (Hasin et al., 2005; Kessler et al., 2007) , and sometimes refractory even to multiple trials of antidepressant medication (Rush et al., 2006) . Thus, it is important to better understand the biological mechanisms of action of current treatments in order to identify early biomarkers that predict later clinical response.
Substantial evidence implicates abnormal glutamatergic neurotransmission in MDD, and glutamate-modulating interventions show promising antidepressant effects (Lener et al., 2016) . Several classes of antidepressant treatments, including selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, monoamine oxidase inhibitors, and electroconvulsive therapy (ECT), have been shown to affect the glutamate system (Skolnick et al., 1996) . Thus, modulation of glutamatergic neurotransmission might represent a shared biological pathway, as yet largely unexplored, amongst these mechanistically diverse antidepressant treatments (Skolnick, 1999) .
Proton magnetic resonance spectroscopy ( 1 H-MRS) enables in vivo measurement of brain glutamate levels, permitting longitudinal examination of changes in glutamatergic activity in individuals receiving antidepressant treatment. Several studies have used 1 H-MRS in this context (Croarkin et al., 2016; Dubin et al., 2016; Godlewska et al., 2015; Grimm et al., 2012; Jarnum et al., 2011; Luborzewski et al., 2007; Merkl et al., 2011; Michael et al., 2003; Njau et al., 2016; Pfleiderer et al., 2003; Taylor et al., 2012; Yang et al., 2014; Zhang et al., 2013) , but are characterized by important methodological limitations. First, many of these studies measured Glx -a composite measure containing both glutamate and glutamine -making them difficult to interpret. Second, with few exceptions (Njau et al., 2016;  http://dx. 
